Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial

BACKGROUND: A proportion of patients with stage IV non-small-cell lung cancer (NSCLC) is predicted to receive third-line treatment. However, currently no standard third-line treatment for NSCLC is available. Anlotinib is an oral, multi-targeted tyrosine kinase (TK) receptor inhibitor, which was appr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Xiyue, Xiang, Miao, Geng, Lidan, Wen, Yixue, Du, Xiaobo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2019
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173357/
https://www.ncbi.nlm.nih.gov/pubmed/31870132
http://dx.doi.org/10.31557/APJCP.2019.20.12.3849

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173357/
https://www.ncbi.nlm.nih.gov/pubmed/31870132
http://dx.doi.org/10.31557/APJCP.2019.20.12.3849

Ejemplares similares